Barclays Trims Jazz Pharmaceuticals (NASDAQ:JAZZ) Target Price to $200.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price objective cut by Barclays from $230.00 to $200.00 in a report issued on Friday, Benzinga reports. They currently have an overweight rating on the specialty pharmaceutical company’s stock.

A number of other brokerages have also commented on JAZZ. Truist Financial reissued a buy rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, March 20th. UBS Group lowered their price target on Jazz Pharmaceuticals from $135.00 to $131.00 and set a neutral rating on the stock in a report on Friday, March 1st. StockNews.com cut shares of Jazz Pharmaceuticals from a strong-buy rating to a buy rating in a research note on Thursday. Needham & Company LLC reiterated a buy rating and issued a $222.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday. Finally, Royal Bank of Canada reiterated an outperform rating and issued a $195.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, February 29th. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of Moderate Buy and a consensus target price of $192.75.

Jazz Pharmaceuticals Stock Down 0.1 %

JAZZ traded down $0.16 during midday trading on Friday, hitting $109.85. 571,215 shares of the company’s stock traded hands, compared to its average volume of 614,775. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.27 and a quick ratio of 1.90. The company has a market cap of $6.92 billion, a PE ratio of 22.68, a price-to-earnings-growth ratio of 1.53 and a beta of 0.63. Jazz Pharmaceuticals has a one year low of $103.01 and a one year high of $146.70. The stock’s fifty day simple moving average is $116.44 and its 200-day simple moving average is $120.94.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.44 by ($0.04). The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1.01 billion. Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. As a group, equities analysts anticipate that Jazz Pharmaceuticals will post 16.24 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 1,936 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total value of $231,623.04. Following the completion of the transaction, the chief accounting officer now owns 8,364 shares of the company’s stock, valued at approximately $1,000,668.96. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CAO Patricia Carr sold 1,936 shares of Jazz Pharmaceuticals stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total transaction of $231,623.04. Following the sale, the chief accounting officer now directly owns 8,364 shares in the company, valued at approximately $1,000,668.96. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Philip L. Johnson acquired 12,000 shares of the stock in a transaction dated Friday, March 1st. The stock was bought at an average price of $119.65 per share, for a total transaction of $1,435,800.00. Following the completion of the purchase, the chief financial officer now owns 27,932 shares in the company, valued at approximately $3,342,063.80. The disclosure for this purchase can be found here. 4.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. grew its holdings in shares of Jazz Pharmaceuticals by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 6,379,053 shares of the specialty pharmaceutical company’s stock worth $825,705,000 after purchasing an additional 29,960 shares during the last quarter. LSV Asset Management boosted its position in Jazz Pharmaceuticals by 2.4% in the third quarter. LSV Asset Management now owns 2,372,177 shares of the specialty pharmaceutical company’s stock valued at $307,055,000 after buying an additional 55,630 shares in the last quarter. Polaris Capital Management LLC grew its stake in Jazz Pharmaceuticals by 13.0% during the first quarter. Polaris Capital Management LLC now owns 1,432,660 shares of the specialty pharmaceutical company’s stock worth $172,521,000 after buying an additional 165,200 shares during the last quarter. FMR LLC increased its holdings in shares of Jazz Pharmaceuticals by 8.1% during the third quarter. FMR LLC now owns 1,333,129 shares of the specialty pharmaceutical company’s stock worth $172,560,000 after buying an additional 100,349 shares in the last quarter. Finally, Ameriprise Financial Inc. increased its holdings in Jazz Pharmaceuticals by 4.6% during the 3rd quarter. Ameriprise Financial Inc. now owns 1,299,612 shares of the specialty pharmaceutical company’s stock valued at $168,222,000 after purchasing an additional 57,717 shares in the last quarter. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.